Bcl2 antagonist of cell death ELISA Kit的详细说明书 检测范围:0.156-10 ng/mL 使用:本试剂仅供科研使用 保存:2-8℃ 有效期:6个月 检测方法:ELISA 产品性状:96T/48T,盒装液体 贮藏条件:2-8°C ELISA试剂盒实验原理: ELISA是以免疫学反应为基础,将抗原、牽9体的特异性反应与酶对底物的高效催化作用相结合...
BCL2antagonist of cell death kinases,phosphatases,and ovarian cancer sensitivity to cisplatin. Bansal N,Marchion DC,Bicaku E,et al. J Gy-necol Oncol . 2012Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, et al. BCL2 antagonist of cell death kinases, phosphatases, ...
中文名称:Bad (Agarose) (Akt1 GST, unactivated (Rac PKa, PKBa) (Agarose) Bcl2 Antagonist of Cell Death) 中文同义词: 英文名称:Bad (Agarose) (Akt1 GST, unactivated (Rac PKa, PKBa) (Agarose) Bcl2 Antagonist of Cell Death) 英文同义词:Bad (Agarose) (Akt1 GST, unactivated (Rac PKa, PK...
Bcl-2-associated X protein (BAX) and Bcl-2 homologous antagonist/killer (BAK) are both known as essential gateways to cell death via mitochondria. Both molecules interact and signal in concert in vivo to modulate IRE1α/XBP1 signaling. Both were found as positive mediators of ER stress.51 ...
ChemicalBook 致力于为化学行业用户提供Bad, Soluble (Bcl2 Antagonist of Cell Death) Recombinant的性质、化学式、分子式、比重、密度,同时也包括Bad, Soluble (Bcl2 Antagonist of Cell Death) Recombinant的沸点、熔点、MSDS、用途、作用、毒性、价格、生产厂家、用途、
For CLLs, primary data are shown for 3 patient specimens that had low spontaneous rates of cell death in culture (Rai stage II [n = 1]; Rai stage I [n = 2]), derived from previously untreated patients. Differences in percentage viability between CLLs treated with apogossypol versus ...
Administering a mixture including a cell delivery agent and a cell death agent; reduced the level of the Bcl-2 antagonist protein Bim present in rheumatoid arthritis synovial tissuedoi:US20080234178 A1The present invention is directed to compositions and methods for treating immune system mediated ...
This was reversed by priming cells with a specific Bcl-2 antagonist prior to reactivation, resulting in increased cell death and decreased HIV DNA in a ... R Sampath,NW Cummins,AD Badley - 《Journal of Cell Death》 被引量: 0发表: 2016年 Oral vitamin C enhances the adrenergic vasoconstrict...
Here, we scrutinized the therapeutic potential and mechanism of action of BDA-366 in CLL and DLBCL. Although BDA-366 displayed selective toxicity against both cell types, the BDA-366-induced cell death did not correlate with Bcl-2-protein levels and also occurred in the absence of Bcl-2. ...
However, also the targeting of Bcl-2’s BH4 domain recently emerged as a promising strategy to drive cancer cell death12,13. One strategy has been to use IP3R-derived peptides (such as BIRD-2; Bcl-2/IP3receptor disrupter-2) that represent the binding site for Bcl-2’s BH4 domain5,...